Business
Regentis Biomaterials (RGNT) Targets Major Gap in Knee Cartilage Repair Market with Off-the-Shelf Regenerative Implant
LOS ANGELES, CA - May 29, 2026 (NEWMEDIAWIRE) - Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC(R), a cell-free hydrogel implant designed to repair knee cartilage damage through a single approximately 10-minute procedure, positi...
About this update from Regentis Biomaterials Ltd.
[{"type":"text","content":"LOS ANGELES, CA - May 29, 2026 (NEWMEDIAWIRE) - Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC(R), a cell-free hydrogel implant designed to repair knee cartilage damage through a single approximately 10-minute procedure, positioning the company to address a major unmet need in orthopedic medicine. While roughly 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, no approved off-the-shelf regenerative solution capable of restoring hyaline-like cartilage currently exists in the U.S. market. Unlike traditional microfracture procedures or complex cell-based therapies that often require multiple surgeries and lengthy preparation, GelrinC(R) is designed as a ready-to-use implant that supports native cartilage regeneration over time. The product has already received CE Mark approval in Europe and is advancing through a pivotal U.S. FDA trial that is now more than 50% enrolled. Regentis is also preparing for potential commercialization, highlighted by a newly patented solvent-free manufacturing process that increased production yield by 400%, alongside ongoing efforts to build physician adoption infrastructure across Europe.","length":1190,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IBN","className":"","disableSlideshowImg":false,"size":{"original":{"width":1249,"height":476,"url":"https://media.zenfs.com/en/newsmediawire_165/63eb95e5f7b0fc4d39e07c2a1aa03dcc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Zv9yBgfY8hUc5GVyBneiYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM2Ng--/https://media.zenfs.com/en/newsmediawire_165/63eb95e5f7b0fc4d39e07c2a1aa03dcc","width":960,"height":366},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/s.vVriakcyIlUqHOTHuBJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI0NA--/https://media.zenfs.com/en/newsmediawire_165/63eb95e5f7b0fc4d39e07c2a1aa03dcc","width":640,"height":244},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/g2SvIN3wto2FPDlOakyWYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05MTQ-/https://media.zenfs.com/en/newsmediawire_165/63eb95e5f7b0fc4d39e07c2a1aa03dcc","width":1200,"height":457}}},{"type":"text","content":"To view the full article, visit https://ibn.fm/TrCv1","length":52,"tagName":"p"},{"type":"text","content":"About Regentis Biomaterials","length":27,"tagName":"p"},{"type":"text","content...